Open an account

Nutriband

NTRB · NASDAQ

$5.85−$0.15 (−2.50%)TodayMarket closed ·
Prev close $6.00

About NTRB

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. The company is headquartered in Orlando, Florida. The company went IPO on 2017-06-20. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. The company is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

Employees
13
Headquarters
Orlando, Florida
Listed
Jun 20, 2017
Sector
Health Care
Industry
Pharmaceuticals
Website
nutriband.com

NTRB key statistics

Market cap
71.11M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
113.25K
Volume
16.69K
Open price
$5.97
High today
$6.05
Low today
$5.80
52 Week high
$9.19
52 Week low
$2.80

Nutriband (NTRB) at a glance

As of Oct 20, 2026, Nutriband (NTRB) shares are priced at $5.85, giving the company a market cap of 71.11M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $5.80 and $6.05. The current price is 0.9% above the day's low and 3.3% below its high.

Volume so far is 16.69K shares, below the average of 113.25K shares a day.

Over the past year Nutriband has ranged from $2.80 to $9.19, and now sits 48% of the way up that range.

Nutriband met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q4 FY26 it reported -$0.08 per share against an estimate of -$1.93.

NTRB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 69.2% on average.

  1. Q3 FY23: reported -$0.14 per share against an estimate of -$0.0612
  2. Q4 FY23: reported -$0.21 per share against an estimate of -$0.0437
  3. Q3 FY24: reported -$0.22 per share against an estimate of $0.00
  4. Q4 FY25: reported -$0.51 per share against an estimate of -$0.1224
  5. Q1 FY26: reported -$0.12 per share against an estimate of -$0.1632
  6. Q2 FY26: reported -$0.18 per share against an estimate of -$0.1734
  7. Q3 FY26: reported -$0.32 per share against an estimate of -$2.17
  8. Q4 FY26: reported -$0.08 per share against an estimate of -$1.93

NTRB news

  • Press releaseGlobe Newswire

    Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders

  • Avi Kapoor

    Why Webuy Global Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Press releaseGlobe Newswire

    Nutriband CEO Publishes Letter to Shareholders

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Press releaseGlobe Newswire

    Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

Similar companies

Companies in the same industry as Nutriband

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.